賽生藥業(06600.HK):Vaborem在內地III期臨床試驗完成全部受試者入組
賽生藥業(06600.HK)公布,新型抗菌藥物Vaborem(注射用美羅培南韋博巴坦)在中國開展的III期臨床試驗已完成全部受試者入組。
公司指出,該研究是在中國正開展的一項隨機、雙盲雙模擬、陽性藥物對照、多中心的III期臨床試驗,旨在評價Vaborem(R)在複雜性尿路感染「cUTI」(包括急性腎盂腎炎)患者中的有效性和安全性,由復旦大學附屬華山醫院教授王明貴和上海交通大學醫學院附屬仁濟醫院教授鄭軍華擔任主要研究者,在全國27家研究中心共入組108例受試者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.